Vitadio Secures €3 Million Investment to Expand its Prescription Digital Therapeutics for Lifestyle-related Conditions

Vitadio specializes in the development of digital health apps validated in clinical studies and approved by national regulators for prescription by healthcare professionals, known as prescription digital therapeutics. Its first product was the first digital therapy approved for the treatment of type 2 diabetes by the German Federal Institute for Drugs and Medical Devices. This milestone led to full coverage for 8 million people in Germany.

Previously, Vitadio raised €1 million from VC fund Nation 1, angel investor Petr Skrla, and Pilulka Lab to develop, validate, and launch its type 2 diabetes product. Building on its success in Germany, Vitadio has now secured an additional €3 million in funding from Italian medtech company Theras Group and a German investor Jafam Holding.

Jan Šomvársky, CEO of Vitadio, stated, "We will use the funds to scale up sales in Germany, develop new therapies, and expand geographically." This expansion will include increasing the company's current headcount of 30 people with additional commercial and research roles to further their mission of empowering people to take control of their health.

Vitadio for diabetes offers a holistic approach to managing type 2 diabetes, helping users identify and achieve lifestyle goals that significantly impact their condition. The product covers various aspects of health, including nutrition, physical activity, sleep, mental well-being, and diabetes self-management. A standout feature is the AI algorithm named ALFRED, which provides real-time automated guidance based on nutritional patterns from meal photos.

Chief Scientific Officer Lenka Röhryová emphasized, "ALFRED provides what dietitians routinely do but in real-time, precisely when it's most relevant to the user." Users also benefit from access to a personal health coach and the opportunity to interact with peers in an in-app community.

Vitadio for diabetes aligns with medical guidelines and has undergone validation in two clinical studies in Germany and the Czech Republic. A third study, in collaboration with the Technical University in Dresden, is nearing completion. The product has demonstrated improvements in diabetes control equivalent to the effects of modern antidiabetic drugs, with users achieving recommended levels of glycated hemoglobin 2.6 times more often compared to standard care.

Lenka Röhryová added, "Vitadio for diabetes not only improves care for patients and healthcare professionals but also saves the system a significant amount of money on medication and the prevention of costly complications." The company reaffirms its commitment to research and clinical validation as integral to its future activities.

Germany was the first country to adopt a reimbursement pathway for digital therapeutics, with other European nations following suit. Jan Šomvársky noted, "Healthcare systems are adopting regulations that make it possible to integrate digital technologies into standard healthcare settings, which was very challenging to achieve in the past."

Currently operating in Germany, the Czech Republic, and Slovakia, Vitadio plans to expand into new countries in 2024. The company's digital platform is poised to support the launch of new therapies from its product research pipeline. Boleslav Kristian, CTO, stated, "We have invested a lot of effort in making our technical platform ready to deliver multiple therapies across multiple countries and multiple regulatory frameworks." Vitadio aspires to modernize the treatment of a wider range of conditions and play a pioneering role in prescription digital therapeutics.